Elagolix and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Elagolix
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Elagolix (Orilissa) can speed up an enzyme in your body called CYP3A4. That same enzyme is what handles cariprazine (Vraylar), a medicine used for mood and psychiatric conditions. Here is the tricky part: cariprazine also relies on this enzyme to create its long-lasting active forms. So speeding up the enzyme could change your cariprazine levels, and honestly the exact net effect has not been studied.
Because of that uncertainty, taking both together is generally not recommended. The good news is this is manageable. Please don't stop or change either medicine on your own. Just talk with your doctor or pharmacist so they can decide the safest plan for you.
Mechanism: Elagolix is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate whose active metabolites (desmethyl- and didesmethyl-cariprazine) are both formed and eliminated via CYP3A4.
- Direction/magnitude: Net effect on total cariprazine active-moiety exposure is unpredictable because CYP3A4 governs both formation and clearance; not formally evaluated.
- Onset: Unspecified; enzyme induction is typically delayed (days to weeks).
- Evidence: Theoretical.
- Severity: Major, combination not recommended.
- Management: Avoid coadministration where possible; if used, monitor closely for altered efficacy or tolerability and individualize dosing with the care team.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
Giving cariprazine (a substrate of CYP3A4) together with a CYP3A4 inducer is not advised. The generation and clearance of cariprazine's active metabolites depend on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall effect remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
Because elagolix can alter how your body processes cariprazine, and the net effect is not well studied, this combination is generally not recommended.
- Keep taking both medications exactly as prescribed until your care team tells you otherwise. Do not stop or adjust anything on your own.
- Your team may choose an alternative, adjust dosing, or watch you more closely for changes in how well your cariprazine is working or any new side effects.
- Tell your pharmacist or prescriber that you are taking both, and report any mood changes, new symptoms, or unusual side effects.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Elagolix and Cariprazine together?
Elagolix may change cariprazine levels in an unpredictable way, so this combination is generally not recommended; keep taking both as prescribed and check with your doctor or pharmacist about the safest plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Elagolix and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Elagolix and Cariprazine interaction managed?
Because elagolix can alter how your body processes cariprazine, and the net effect is not well studied, this combination is generally not recommended. Keep taking both medications exactly as prescribed until your care team tells you otherwise. Do not stop or adjust anything on your own. Your team may choose an alternative, adjust dosing, or watch you more closely for changes in how well your carip… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Elagolix or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Elagolix
Keep reading about Cariprazine
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist